Chimeric Human Papillomavirus-16 Virus-like Particles Presenting HIV-1 P18I10 Peptide: Expression, Purification, Bio-Physical Properties and Immunogenicity in BALB/c Mice
Human papillomavirus (HPV) vaccines based on HPV L1 virus-like particles (VLPs) are already licensed but not accessible worldwide. About 38.0 million people were living with HIV in 2020 and there is no HIV vaccine yet. Therefore, safe, effective, and affordable vaccines against both viruses are an u...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-04-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/24/9/8060 |
_version_ | 1797602482369593344 |
---|---|
author | Chun-Wei Chen Narcís Saubi Joan Joseph-Munné |
author_facet | Chun-Wei Chen Narcís Saubi Joan Joseph-Munné |
author_sort | Chun-Wei Chen |
collection | DOAJ |
description | Human papillomavirus (HPV) vaccines based on HPV L1 virus-like particles (VLPs) are already licensed but not accessible worldwide. About 38.0 million people were living with HIV in 2020 and there is no HIV vaccine yet. Therefore, safe, effective, and affordable vaccines against both viruses are an urgent need. In this study, the HIV-1 P18I10 CTL peptide from the V3 loop of HIV-1 gp120 glycoprotein was inserted into the HPV16 L1 protein to construct chimeric HPV:HIV (L1:P18I10) VLPs. Instead of the traditional baculovirus expression vector/insect cell (BEVS/IC) system, we established an alternative mammalian 293F cell-based expression system using cost-effective polyethylenimine-mediated transfection for L1:P18I10 protein production. Compared with conventional ultracentrifugation, we optimized a novel chromatographic purification method which could significantly increase L1:P18I10 VLP recovery (~56%). Chimeric L1:P18I10 VLPs purified from both methods were capable of self-assembling to integral particles and shared similar biophysical and morphological properties. After BALB/c mice immunization with 293F cell-derived and chromatography-purified L1:P18I10 VLPs, almost the same titer of anti-L1 IgG (<i>p</i> = 0.6409) was observed as Gardasil anti-HPV vaccine-immunized mice. Significant titers of anti-P18I10 binding antibodies (<i>p</i> < 0.01%) and P18I10-specific IFN-γ secreting splenocytes (<i>p</i> = 0.0002) were detected in L1:P18I10 VLP-immunized mice in comparison with licensed Gardasil-9 HPV vaccine. Furthermore, we demonstrated that insertion of HIV-1 P18I10 peptide into HPV16 L1 capsid protein did not affect the induction in anti-L1 antibodies. All in all, we expected that the mammalian cell expression system and chromatographic purification methods could be time-saving, cost-effective, scalable platforms to engineer bivalent VLP-based vaccines against HPV and HIV-1 |
first_indexed | 2024-03-11T04:17:38Z |
format | Article |
id | doaj.art-eaf371ed23894b19bb062aac4499c198 |
institution | Directory Open Access Journal |
issn | 1661-6596 1422-0067 |
language | English |
last_indexed | 2024-03-11T04:17:38Z |
publishDate | 2023-04-01 |
publisher | MDPI AG |
record_format | Article |
series | International Journal of Molecular Sciences |
spelling | doaj.art-eaf371ed23894b19bb062aac4499c1982023-11-17T23:04:30ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672023-04-01249806010.3390/ijms24098060Chimeric Human Papillomavirus-16 Virus-like Particles Presenting HIV-1 P18I10 Peptide: Expression, Purification, Bio-Physical Properties and Immunogenicity in BALB/c MiceChun-Wei Chen0Narcís Saubi1Joan Joseph-Munné2Department of Biomedical Sciences, University of Barcelona, 08036 Barcelona, SpainVall d’Hebron Research Institute (VHIR), 08035 Barcelona, SpainVall d’Hebron Research Institute (VHIR), 08035 Barcelona, SpainHuman papillomavirus (HPV) vaccines based on HPV L1 virus-like particles (VLPs) are already licensed but not accessible worldwide. About 38.0 million people were living with HIV in 2020 and there is no HIV vaccine yet. Therefore, safe, effective, and affordable vaccines against both viruses are an urgent need. In this study, the HIV-1 P18I10 CTL peptide from the V3 loop of HIV-1 gp120 glycoprotein was inserted into the HPV16 L1 protein to construct chimeric HPV:HIV (L1:P18I10) VLPs. Instead of the traditional baculovirus expression vector/insect cell (BEVS/IC) system, we established an alternative mammalian 293F cell-based expression system using cost-effective polyethylenimine-mediated transfection for L1:P18I10 protein production. Compared with conventional ultracentrifugation, we optimized a novel chromatographic purification method which could significantly increase L1:P18I10 VLP recovery (~56%). Chimeric L1:P18I10 VLPs purified from both methods were capable of self-assembling to integral particles and shared similar biophysical and morphological properties. After BALB/c mice immunization with 293F cell-derived and chromatography-purified L1:P18I10 VLPs, almost the same titer of anti-L1 IgG (<i>p</i> = 0.6409) was observed as Gardasil anti-HPV vaccine-immunized mice. Significant titers of anti-P18I10 binding antibodies (<i>p</i> < 0.01%) and P18I10-specific IFN-γ secreting splenocytes (<i>p</i> = 0.0002) were detected in L1:P18I10 VLP-immunized mice in comparison with licensed Gardasil-9 HPV vaccine. Furthermore, we demonstrated that insertion of HIV-1 P18I10 peptide into HPV16 L1 capsid protein did not affect the induction in anti-L1 antibodies. All in all, we expected that the mammalian cell expression system and chromatographic purification methods could be time-saving, cost-effective, scalable platforms to engineer bivalent VLP-based vaccines against HPV and HIV-1https://www.mdpi.com/1422-0067/24/9/8060HIV-1HPV16virus-like particlevaccinesBEVS/IC systemmammalian 293F cell expression system |
spellingShingle | Chun-Wei Chen Narcís Saubi Joan Joseph-Munné Chimeric Human Papillomavirus-16 Virus-like Particles Presenting HIV-1 P18I10 Peptide: Expression, Purification, Bio-Physical Properties and Immunogenicity in BALB/c Mice International Journal of Molecular Sciences HIV-1 HPV16 virus-like particle vaccines BEVS/IC system mammalian 293F cell expression system |
title | Chimeric Human Papillomavirus-16 Virus-like Particles Presenting HIV-1 P18I10 Peptide: Expression, Purification, Bio-Physical Properties and Immunogenicity in BALB/c Mice |
title_full | Chimeric Human Papillomavirus-16 Virus-like Particles Presenting HIV-1 P18I10 Peptide: Expression, Purification, Bio-Physical Properties and Immunogenicity in BALB/c Mice |
title_fullStr | Chimeric Human Papillomavirus-16 Virus-like Particles Presenting HIV-1 P18I10 Peptide: Expression, Purification, Bio-Physical Properties and Immunogenicity in BALB/c Mice |
title_full_unstemmed | Chimeric Human Papillomavirus-16 Virus-like Particles Presenting HIV-1 P18I10 Peptide: Expression, Purification, Bio-Physical Properties and Immunogenicity in BALB/c Mice |
title_short | Chimeric Human Papillomavirus-16 Virus-like Particles Presenting HIV-1 P18I10 Peptide: Expression, Purification, Bio-Physical Properties and Immunogenicity in BALB/c Mice |
title_sort | chimeric human papillomavirus 16 virus like particles presenting hiv 1 p18i10 peptide expression purification bio physical properties and immunogenicity in balb c mice |
topic | HIV-1 HPV16 virus-like particle vaccines BEVS/IC system mammalian 293F cell expression system |
url | https://www.mdpi.com/1422-0067/24/9/8060 |
work_keys_str_mv | AT chunweichen chimerichumanpapillomavirus16viruslikeparticlespresentinghiv1p18i10peptideexpressionpurificationbiophysicalpropertiesandimmunogenicityinbalbcmice AT narcissaubi chimerichumanpapillomavirus16viruslikeparticlespresentinghiv1p18i10peptideexpressionpurificationbiophysicalpropertiesandimmunogenicityinbalbcmice AT joanjosephmunne chimerichumanpapillomavirus16viruslikeparticlespresentinghiv1p18i10peptideexpressionpurificationbiophysicalpropertiesandimmunogenicityinbalbcmice |